Obesity not only runs counter to the aesthetics of people, but also causes many chronic diseases. Some studies have shown that body mass index (BMI) is related to the risk of cancer in certain parts (such as the digestive system), but there is no unified conclusion on the relationship with cancer in other parts. An umbrella review published in Annals of Oncology at the end of 2017, comprehensively analyzing the relationship between 26 BMI and cancer riskta analysis, and strive to bring the most authoritative conclusions to readers.
The study only included evaluation of the quantitative response between BMI and the risk of cancer analysis, a total of 26 articles. Use umbrella review (ie multiple meta analysis to review), re-analyzed the relationship between BMI and 20 types of cancer.
The results of the study showed that five types of cancer (leukemia, multiple myeloma, pancreatic cancer, endometrial cancer, rectal cancer, and renal cell carcinoma) had the highest correlation strength with BMI; three types of cancer (malignant melanoma, non-Hodgkin) Lymphoma and esophageal adenocarcinoma) and BMI reach a moderate level of strength; for brain and central nervous system tumors, breast cancer, colon cancer, gallbladder cancer, lung cancer, liver cancer, ovarian cancer and thyroid cancer, there is a low-grade BMI Degree of association; there is no association between the occurrence of bladder cancer, gastric cancer and prostate cancer and BMI.
The relationship between increased BMI and the occurrence of cancer varies greatly between different cancers. According to analysis, the occurrence of leukemia, multiple myeloma, pancreatic cancer, endometrial cancer, rectal cancer and renal cell carcinoma is strongly associated with the increase in BMI.
Body mass index and 20-specific cancers: re-analyses of dose-response meta-analyses of observational studies. Ann Oncol. 2017 Dec 28. doi: 10.1093 / annonc / mdx819.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
- Susan Hauhttps://cancerfax.com/author/susan/
- Susan Hauhttps://cancerfax.com/author/susan/
- Susan Hauhttps://cancerfax.com/author/susan/
- Susan Hauhttps://cancerfax.com/author/susan/